Enterprise Sponsor: Italy
Olon, one of our Road To CPhI Milano sponsors discuss how they are preparing to face the future of healthcare.
The Mission of the Company
After a string of recent acquisitions, Olon has updated the company mission and vision to reflect goals for 2020 and beyond. This mission now reads to “Challenge and innovate the way we deliver science to improve the health of all human beings.” This means that Olon is committed to stepping back to analyze every decision objectively. They will also implement “creative ideas, creating a pathway for prompt and sustainable solutions in the life science industry.” This gives Olon the flexibility and opportunity needed to step outside the box, finding new and sustainable solutions to their clients’ complex problems.
The importance of Olon’s work cannot be overestimated, as their efforts bring positive changes to the lives of millions of human beings across the globe. They drive timelines for bringing new medication to patients, delivering quality and affordable treatments.
In just two years, Olon has doubled in size. In 2017, the company acquired three plants from Infa group — two plants are located in Italy (Segrate and Casaletto) and one is in Spain (Derivados Quimicos, in Murcia). In 2019, Olon acquired Capua Bioservices, with a facility in Italy and a former Novartis site in Mahad, India. With a total network of 11 manufacturing plants, Olon is a production leader for APIs.
The company has also recently invested in new technologies aiming to increase production capabilities. These investments include a fluorination plant, where synthesis can take place using hydrofluoric acid and its derivatives, and in flow chemistry. The company is committed to positively transitioning from a classic batch system to continuous manufacturing, saving on cost and decreasing environmental impact. They have heavily invested in expanding their capacity using high-containment technology (reaction/isolation/drying/micronization). They are also introducing spray drying and wet milling, which are the new frontiers of the drying and granulation processes, and lead to higher production performances.
In November 2019, Olon announced a collaboration with Novartis to ensure the sustainable supply of high-quality hydroxyurea in Ghana and other African countries. Hydroxyurea is commonly used to treat both adults and children with sickle cell disease. In October 2018, Ghana’s FDA granted marketing authorization to hydroxyurea, making it the first time that the drug was available for this indication in Ghana. Olon is proud to collaborate with Novartis and its partners to help make hydroxyurea more broadly available in a sustainable way. As a demonstration of their commitment to patients with sickle cell disease, and this program, Olon has sponsored approximately 12,000 treatments of hydroxyurea.
Following the updated mission and vision based on creativity, sustainability, and the improvement for all human beings’ lives, Olon is focused on developing innovative products in cooperation with customers and on an exclusive basis, as they continue to be a reliable partner for pharma companies. The company has plans for future growth and is evaluating new M&A opportunities.